Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 4/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 7/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429416 | 1.00 | GNAO1 (0.39) | GNAO1GNAI3GNAI1BCHESPHK1 | |
| SCHEMBL26604172 | 0.98 | GNAI3 (0.37) | GNAO1GNAI3GNAI1BCHESPHK1 | |
| SCHEMBL19176677 | 0.90 | GNAO1 (0.45) | GNAO1GNAI3GNAI1BCHESPHK1 | |
| SCHEMBL19252722 | 0.90 | GNAO1 (0.45) | GNAO1GNAI3GNAI1BCHESPHK1 | |
| SCHEMBL19176725 | 0.90 | GNAO1 (0.45) | GNAO1GNAI3GNAI1BCHESPHK1 | |
| SCHEMBL26610208 | 0.88 | GNAO1 (0.39) | GNAO1GNAI3GNAI1BCHESPHK1 | |
| SCHEMBL18399592 | 0.88 | GNAO1 (0.39) | GNAO1GNAI3GNAI1BCHESPHK1 | |
| SCHEMBL21158407 | 0.87 | — | — | |
| SCHEMBL22648455 | 0.87 | — | — | |
| SCHEMBL22855747 | 0.86 | GNAO1 (0.38) | GNAO1GNAI3GNAI1BCHESPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | GNAO1 3070/4885GNAI3 1955/4885GNAI1 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.